Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Dec;16(6):430-43.
doi: 10.3109/13625187.2011.614029. Epub 2011 Oct 13.

Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen

Diana Mansour  1 , Carole Verhoeven, Werner Sommer, Edith Weisberg, Surasak Taneepanichskul, Gian Benedetto Melis, Inger Sundström-Poromaa, Tjeerd Korver
Affiliations
Free PMC article
Randomized Controlled Trial

Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen

Diana Mansour et al. Eur J Contracept Reprod Health Care. 2011 Dec.
Free PMC article

Abstract

Objectives: The primary objective was to assess the efficacy, cycle control and tolerability of a monophasic combined oral contraceptive (COC) containing nomegestrol acetate (NOMAC) and 17β-oestradiol (E2). Effects on acne were evaluated as a secondary objective. Results were compared to those of a COC containing drospirenone (DRSP) and ethinylestradiol (EE).

Methods: Women (aged 18-50 years) were randomised to receive NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=1591) or DRSP/EE (3 mg/30 μg) in a 21/7-day regimen (n=535) for 13 cycles.

Results: Estimated Pearl Indices for NOMAC/E2 and DRSP/EE were 0.38 and 0.81 in women aged≤35 years and 0.31 and 0.66 for all women (18-50 years), respectively. Scheduled withdrawal bleedings were shorter and lighter among users of NOMAC/E2 and were sometimes absent altogether. Intracyclic bleeding/spotting was infrequent in both groups, and decreased over time. Type and frequency of adverse events were similar to those typically reported for COCs.

Conclusions: These data show that NOMAC/E2 provides high contraceptive efficacy with acceptable cycle control as well as an overall adverse event profile similar to that of DRSP/EE.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient flow through the trial. NO MAC, nomegestrol acetate; E2, oestradiol; EE, ethinylestradiol; DRSP, drospirenone; AE, adverse event.
Figure 2
Figure 2
Mean number of bleeding-spotting days per 91-day reference periods for (A) NOMAC/E2 and (B) DRSP/EE. NOMAC, nomegestrol acetate; E2, oestradiol; EE, ethinylestradiol; DRSP drospirenone.
Figure 3
Figure 3
(A) Incidences (%) and (B) duration (median number of days) of breakthrough bleeding-spotting for N0MAC/E2 (grey bars) and DRSP/EE (black bars). The incidences were compared statistically between the treatment groups. *p < 0.05 vs. DRSP/EE. NOMAC, nomegestrol acetate; E2, oestradiol; EE, ethinylestradiol; DRSP drospirenone.
Figure 4
Figure 4
(A) Incidences of absence of withdrawal bleeding (%) and (B) duration of withdrawal bleeding (median number of days) for NOMAC/E2 (grey bars) and DRSP/EE (black bars). The incidences were compared statistically between the treatment groups. *p < 0.05 vs. DRSP/EE. NOMAC, nomegestrol acetate; E2, oestradiol; EE, ethinylestradiol; DRSP drospirenone.
Figure 5
Figure 5
(A) Prevalence (%) of acne and (B) changes in acne severity (%) from baseline to last measurement during treatment with NOMAC/E2 (grey bars) and DRSP/EE (black bars). NOMAC, nomegestrol acetate; E2, oestradiol; EE, ethinylestradiol; DRSP drospirenone; LM, last measurement.
See this image and copyright information in PMC

References

    1. UN Department of Economic and Social Affairs Population Division. World Contraceptive Use. Accessed 11 June 2010 from: http://www.un.org/esa/population/publications/contraceptive2009/contrace....
    1. Rosenberg MJ, Meyers A, Roy V. Efficacy cycle control, and side effects of low- and lower-dose oral contraceptives: A randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception. 999;60:321–9. - PubMed
    1. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: Final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344–54. - PubMed
    1. Cerel-Suhl SL, Yeager BF. Update on oral contraceptive pills. Am Fam Physician. 1999;60:2073–84. - PubMed
    1. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update. 2006;12:169–78. - PubMed

Publication types

MeSH terms